Myriad Genetics, Inc. (MYGN)
USD 13.25
(-4.12%)
USD 13.25
(-4.12%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 600.1 Million USD | -11.97% |
| 2021 | 681.7 Million USD | 4.35% |
| 2020 | 653.3 Million USD | 1.86% |
| 2019 | 641.4 Million USD | 0.0% |
| 2018 | 641.4 Million USD | 19.24% |
| 2017 | 537.9 Million USD | -2.34% |
| 2016 | 550.8 Million USD | 28.18% |
| 2015 | 429.7 Million USD | -2.67% |
| 2014 | 441.5 Million USD | 11.89% |
| 2013 | 394.57 Million USD | 29.14% |
| 2012 | 305.54 Million USD | 21.72% |
| 2011 | 251.02 Million USD | 27.04% |
| 2010 | 197.59 Million USD | 7.8% |
| 2009 | 183.28 Million USD | 16.89% |
| 2008 | 156.79 Million USD | -40.43% |
| 2007 | 263.2 Million USD | 51.23% |
| 2006 | 174.04 Million USD | 31.63% |
| 2005 | 132.22 Million USD | 28.59% |
| 2004 | 102.82 Million USD | 20.22% |
| 2003 | 85.53 Million USD | 8.11% |
| 2002 | 79.11 Million USD | 28.06% |
| 2001 | 61.77 Million USD | 21.38% |
| 2000 | 50.89 Million USD | 13.46% |
| 1999 | 44.85 Million USD | 18.67% |
| 1998 | 37.8 Million USD | -0.79% |
| 1997 | 38.1 Million USD | 27.42% |
| 1996 | 29.9 Million USD | 74.85% |
| 1995 | 17.1 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 239.4 Million USD | 37.43% |
| 2023 Q1 | 174.2 Million USD | 2.53% |
| 2023 Q3 | 194.4 Million USD | -18.8% |
| 2022 Q3 | 151 Million USD | 2.44% |
| 2022 Q2 | 147.4 Million USD | 11.84% |
| 2022 Q4 | 169.9 Million USD | 12.52% |
| 2022 Q1 | 131.8 Million USD | -16.64% |
| 2022 FY | 600.1 Million USD | -11.97% |
| 2021 Q3 | 199 Million USD | 28.97% |
| 2021 FY | 681.7 Million USD | 4.35% |
| 2021 Q2 | 154.3 Million USD | -8.48% |
| 2021 Q1 | 168.6 Million USD | 11.58% |
| 2021 Q4 | 158.1 Million USD | -20.55% |
| 2020 Q2 | 124.8 Million USD | -18.22% |
| 2020 FY | 653.3 Million USD | 1.86% |
| 2020 Q3 | 141.7 Million USD | 13.54% |
| 2020 Q4 | 151.1 Million USD | 6.63% |
| 2020 Q1 | 152.6 Million USD | -1.17% |
| 2019 Q3 | 156.8 Million USD | -8.14% |
| 2019 FY | 641.4 Million USD | 0.0% |
| 2019 Q1 | 162.1 Million USD | 2.86% |
| 2019 Q4 | 154.4 Million USD | -1.53% |
| 2019 Q2 | 170.7 Million USD | 5.31% |
| 2018 Q1 | 133.6 Million USD | 1.06% |
| 2018 FY | 641.4 Million USD | 19.24% |
| 2018 Q2 | 139.1 Million USD | 4.12% |
| 2018 Q3 | 151 Million USD | 8.55% |
| 2018 Q4 | 157.6 Million USD | 4.37% |
| 2017 Q1 | 139.7 Million USD | 0.58% |
| 2017 FY | 537.9 Million USD | -2.34% |
| 2017 Q4 | 132.2 Million USD | -0.6% |
| 2017 Q3 | 133 Million USD | -5.61% |
| 2017 Q2 | 140.9 Million USD | 0.86% |
| 2016 FY | 550.8 Million USD | 28.18% |
| 2016 Q2 | 110.8 Million USD | 2.88% |
| 2016 Q3 | 131.3 Million USD | 18.5% |
| 2016 Q4 | 138.9 Million USD | 5.79% |
| 2016 Q1 | 107.7 Million USD | 0.19% |
| 2015 FY | 429.7 Million USD | -2.67% |
| 2015 Q3 | 103.7 Million USD | -10.76% |
| 2015 Q4 | 107.5 Million USD | 3.66% |
| 2015 Q2 | 116.2 Million USD | 7.64% |
| 2015 Q1 | 107.95 Million USD | -2.04% |
| 2014 Q3 | 108.05 Million USD | 3.37% |
| 2014 Q4 | 110.19 Million USD | 1.99% |
| 2014 Q1 | 101.02 Million USD | 6.42% |
| 2014 FY | 441.5 Million USD | 11.89% |
| 2014 Q2 | 104.53 Million USD | 3.47% |
| 2013 Q2 | 86.12 Million USD | 10.11% |
| 2013 Q3 | 94.08 Million USD | 9.24% |
| 2013 Q4 | 94.93 Million USD | 0.9% |
| 2013 FY | 394.57 Million USD | 29.14% |
| 2013 Q1 | 78.22 Million USD | 6.18% |
| 2012 FY | 305.54 Million USD | 21.72% |
| 2012 Q1 | 66.45 Million USD | 8.53% |
| 2012 Q2 | 68.72 Million USD | 3.42% |
| 2012 Q3 | 67.52 Million USD | -1.74% |
| 2012 Q4 | 73.67 Million USD | 9.1% |
| 2011 Q4 | 61.22 Million USD | 12.1% |
| 2011 Q1 | 49.41 Million USD | -0.79% |
| 2011 FY | 251.02 Million USD | 27.04% |
| 2011 Q3 | 54.61 Million USD | 2.84% |
| 2011 Q2 | 53.11 Million USD | 7.48% |
| 2010 FY | 197.59 Million USD | 7.8% |
| 2010 Q4 | 49.8 Million USD | 10.06% |
| 2010 Q3 | 45.25 Million USD | 0.46% |
| 2010 Q2 | 45.05 Million USD | -3.58% |
| 2010 Q1 | 46.72 Million USD | -0.93% |
| 2009 FY | 183.28 Million USD | 16.89% |
| 2009 Q1 | 53.94 Million USD | -2.89% |
| 2009 Q3 | 44.34 Million USD | 1467.08% |
| 2009 Q2 | -3.24 Million USD | -106.01% |
| 2009 Q4 | 47.16 Million USD | 6.35% |
| 2008 Q3 | 50.54 Million USD | -44.81% |
| 2008 FY | 156.79 Million USD | -40.43% |
| 2008 Q4 | 55.55 Million USD | 9.9% |
| 2008 Q2 | 91.59 Million USD | 49.37% |
| 2008 Q1 | 61.31 Million USD | 6.11% |
| 2007 FY | 263.2 Million USD | 51.23% |
| 2007 Q4 | 57.78 Million USD | 10.05% |
| 2007 Q3 | 52.51 Million USD | 4.73% |
| 2007 Q2 | 50.14 Million USD | 18.02% |
| 2007 Q1 | 42.48 Million USD | 132.96% |
| 2006 FY | 174.04 Million USD | 31.63% |
| 2006 Q2 | 37.94 Million USD | 10.76% |
| 2006 Q1 | 34.25 Million USD | 11.74% |
| 2006 Q3 | 40.43 Million USD | 6.58% |
| 2006 Q4 | 18.23 Million USD | -54.9% |
| 2005 Q4 | 30.65 Million USD | 4.41% |
| 2005 FY | 132.22 Million USD | 28.59% |
| 2005 Q3 | 29.36 Million USD | 0.62% |
| 2005 Q2 | 29.18 Million USD | 15.01% |
| 2005 Q1 | 25.37 Million USD | 0.75% |
| 2004 Q2 | 22.15 Million USD | 4.47% |
| 2004 Q1 | 21.21 Million USD | 0.62% |
| 2004 Q4 | 25.18 Million USD | 9.08% |
| 2004 Q3 | 23.08 Million USD | 4.19% |
| 2004 FY | 102.82 Million USD | 20.22% |
| 2003 Q2 | 20.1 Million USD | 6.71% |
| 2003 Q3 | 21.08 Million USD | 4.88% |
| 2003 Q4 | 21.08 Million USD | -0.0% |
| 2003 FY | 85.53 Million USD | 8.11% |
| 2003 Q1 | 18.83 Million USD | -12.43% |
| 2002 Q4 | 21.51 Million USD | 15.28% |
| 2002 FY | 79.11 Million USD | 28.06% |
| 2002 Q1 | 14.65 Million USD | -0.28% |
| 2002 Q2 | 18.54 Million USD | 26.6% |
| 2002 Q3 | 18.66 Million USD | 0.61% |
| 2001 Q4 | 14.69 Million USD | 5.81% |
| 2001 Q3 | 13.88 Million USD | 15.19% |
| 2001 Q1 | 12.67 Million USD | -5.62% |
| 2001 Q2 | 12.05 Million USD | -4.9% |
| 2001 FY | 61.77 Million USD | 21.38% |
| 2000 Q1 | 12.45 Million USD | 20.87% |
| 2000 Q2 | 12.44 Million USD | -0.08% |
| 2000 FY | 50.89 Million USD | 13.46% |
| 2000 Q3 | 12.73 Million USD | 2.36% |
| 2000 Q4 | 13.43 Million USD | 5.47% |
| 1999 Q2 | 9.7 Million USD | 2.11% |
| 1999 Q1 | 9.5 Million USD | 0.0% |
| 1999 Q4 | 10.3 Million USD | 6.19% |
| 1999 FY | 44.85 Million USD | 18.67% |
| 1999 Q3 | 9.7 Million USD | 0.0% |
| 1998 Q4 | 9.5 Million USD | 3.26% |
| 1998 FY | 37.8 Million USD | -0.79% |
| 1998 Q2 | 10.7 Million USD | 11.46% |
| 1998 Q3 | 9.2 Million USD | -14.02% |
| 1998 Q1 | 9.6 Million USD | 10.34% |
| 1997 Q4 | 8.7 Million USD | -4.4% |
| 1997 Q2 | 8.5 Million USD | 16.44% |
| 1997 Q3 | 9.1 Million USD | 7.06% |
| 1997 FY | 38.1 Million USD | 27.42% |
| 1997 Q1 | 7.3 Million USD | -3.95% |
| 1996 Q1 | 5 Million USD | 38.89% |
| 1996 FY | 29.9 Million USD | 74.85% |
| 1996 Q2 | 5.3 Million USD | 6.0% |
| 1996 Q3 | 6.4 Million USD | 20.75% |
| 1996 Q4 | 7.6 Million USD | 18.75% |
| 1995 Q4 | 3.6 Million USD | 0.0% |
| 1995 FY | 17.1 Million USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | -302.771% |
| Prenetics Global Limited | 60.73 Million USD | -888.037% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -3587.93% |
| CareDx, Inc | 277.76 Million USD | -116.044% |
| Exact Sciences Corporation | 2.06 Billion USD | 70.876% |
| Exagen Inc. | 52.29 Million USD | -1047.572% |
| Inotiv, Inc. | 246.9 Million USD | -143.051% |
| Guardant Health, Inc. | 901.62 Million USD | 33.442% |
| Biodesix, Inc. | 77.41 Million USD | -675.133% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -15196.631% |
| Precipio, Inc. | 13.63 Million USD | -4300.205% |
| iSpecimen Inc. | 16.27 Million USD | -3586.737% |
| Natera, Inc. | 938.98 Million USD | 36.091% |
| Aspira Women's Health Inc. | 24.11 Million USD | -2388.596% |
| Standard BioTools Inc. | 113.48 Million USD | -428.774% |
| 23andMe Holding Co. | 420.73 Million USD | -42.632% |
| Castle Biosciences, Inc. | 242.78 Million USD | -147.175% |
| Personalis, Inc. | 128.14 Million USD | -368.301% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | -442.954% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | -3539.899% |
| OpGen, Inc. | 30.65 Million USD | -1857.403% |
| T2 Biosystems, Inc. | 41.49 Million USD | -1346.233% |
| ICON Public Limited Company | 755.64 Million USD | 20.584% |
| NeoGenomics, Inc. | 341.25 Million USD | -75.852% |
| Star Equity Holdings, Inc. | 16.27 Million USD | -3587.93% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 45.088% |
| RadNet, Inc. | 268.87 Million USD | -123.186% |
| MDxHealth SA | 71.25 Million USD | -742.175% |
| Psychemedics Corporation | 11.33 Million USD | -5194.689% |
| Illumina, Inc. | 3.81 Billion USD | 84.262% |
| Check-Cap Ltd. | 19.28 Million USD | -3011.422% |
| Twist Bioscience Corporation | 354.18 Million USD | -69.434% |
| DarioHealth Corp. | 62.17 Million USD | -865.21% |
| Fulgent Genetics, Inc. | 171.9 Million USD | -249.086% |
| Sera Prognostics, Inc. | 39.91 Million USD | -1403.369% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | -5603.974% |
| OPKO Health, Inc. | 574.68 Million USD | -4.422% |
| Medpace Holdings, Inc. | 187.68 Million USD | -219.746% |
| Neogen Corporation | 405.23 Million USD | -48.086% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | -5025.205% |
| Prenetics Global Limited | 60.73 Million USD | -888.037% |
| Mainz Biomed B.V. | 27.15 Million USD | -2109.96% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -6746.671% |
| Trinity Biotech plc | 46.49 Million USD | -1190.676% |
| Neuronetics, Inc. | 82.25 Million USD | -629.525% |
| Sotera Health Company | 300.46 Million USD | -99.723% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | -6746.671% |